Publications

Adaptive Generalized Elliptical Slice Sampling (2026)

N. Marco, S.T. Tokdar

Mixed Membership Models for Multilevel Functional Data (2026)

D. Telesca, N. Marco, E. Landry

Covariate Adjusted Functional Mixed Membership Models (2025)

N. Marco, D. Şentürk, S. Jeste, C. DiStefano, A. Dickinson, D. Telesca

Bayesian Covariance Regression in Functional Data Analysis with Applications to Functional Brain Imaging (2025)

J. Shamshoian, N. Marco, D. Şentürk, S. Jeste, D. Telesca

Modeling Neural Switching via Drift-Diffusion Models (2024)

N. Marco, J.M. Groh, S.T. Tokdar

Flexible Regularized Estimation in High-Dimensional Mixed Membership Models (2024)

N. Marco, D. Şentürk, S. Jeste, C.C. DiStefano, A. Dickinson, D. Telesca

Functional Mixed Membership Models (2024)

N. Marco, D. Şentürk, S. Jeste, C. DiStefano, A. Dickinson, D. Telesca

Germline Radiosensitivity Biomarker for Radiation-Induced GU Toxicity Following Radiation Therapy in Localized Prostate Cancer (GARUDA): Two-Year Outcomes of a Phase II Clinical Trial (2026)

J.E. Juarez Casillas, P. Jamshidian, M.U. Casado, K. Flores, N. Marco, M.L. Steinberg, A. Lee, M. Xiang, L.F. Valle, A. Stube, D. Telesca, J.B. Weidhaas, A.U. Kishan

Germline microRNA-based signatures predict toxicity and response to anti-CTLA-4 therapy (2025)

J.B. Weidhaas, K.M. McGreevy, N. Marco, N. Sundahl, C.R. Cabanski, C. Spencer, T. LaVallee, P. Ost, D. Telesca

Early findings from the GARUDA trial: The impact of a genetic signature of late radiation toxicity on prostate cancer treatment decision making. (2023)

J.B. Weidhaas, N. Marco, M.L. Steinberg, A. Lee, M. Xiang, L.F. Valle, M. Casado, A. Stube, D. Telesca, A.U. Kishan

Application of a genetic signature of late GU toxicity in SCIMITAR, a Post-op SBRT trial (2023)

A.U. Kishan, N. Marco, T.M. Ma, M.L. Steinberg, A. Sachdeva, M. Cao, L.K. Ballas, E. Rietdorf, D. Telesca, J.B. Weidhaas

Viral burden and clearance in asymptomatic COVID-19 Patients (2022)

A.B. Gunatilaka, N. Marco, G.H. Read, M. Sweeney, G. Regan, C. Tsang, et al., J.B. Weidhaas

Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy (2022)

J. Weidhaas, N. Marco, A.W. Scheffler, A. Kalbasi, K. Wilenius, E. Rietdorf, et al., D. Telesca

Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation (2022)

A.U. Kishan, N. Marco, M.B. Schulz-Jaavall, M.L. Steinberg, P.T. Tran, J.E. Juarez, et al., J.B. Weidhaas